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It is well recognized that mitochondrial dysfunction contributes to neurodegeneration occurring in Alzheimer’s disease (AD).
However, evidences of mitochondrial defects in AD peripheral cells are still inconclusive. Here, some mitochondrial-encoded
and nuclear-encoded proteins, involved in maintaining the correct mitochondria machine, were investigated in terms of protein
expression and enzymatic activity in peripheral blood mononuclear cells (PBMCs) isolated from AD and Mild Cognitive
Impairment (MCI) patients and healthy subjects. In additionmitochondrial DNA copy numberwasmeasured by real time PCR.We
found some differences and some similarities between AD and MCI patients when compared with healthy subjects. For example,
cytochrome C and cytochrome B were decreased in AD, while MCI showed only a statistical reduction of cytochrome C. On
the other hand, both AD and MCI blood cells exhibited highly nitrated MnSOD, index of a prooxidant environment inside the
mitochondria. TFAM, a regulator of mitochondrial genome replication and transcription, was decreased in both AD and MCI
patients’ blood cells.Moreover also themitochondrialDNAamountwas reduced in PBMCs fromboth patient groups. In conclusion
these data confirmed peripheral mitochondria impairment in AD and demonstrated that TFAM and mtDNA amount reduction
could be two features of early events occurring in AD pathogenesis.
1. Introduction
Alzheimer’s disease (AD) is the most common form of
dementia among the elderly, characterized by progressive
memory loss and cognitive decline. AD affects millions of
people worldwide and the number of AD cases is going to
increase with longer life expectancy. For almost twenty years,
the beta amyloid cascade theory has dominated thinking and
research efforts in the comprehension and cure of this disease
[1]. This theory derived largely from the characterization of
rare disease-causing mutations in three genes, which code
for amyloid-𝛽 protein precursor (A𝛽PP), Presenilin 1, and
Presenilin 2, all linked to amyloid-𝛽 metabolisms [2]. By
contrast with familial cases, sporadic forms of the disease are
very commonand represent nearly 95%of cases [3]. Although
the amyloid cascade hypothesis has also been extrapolated
to explain sporadic AD, it does not completely explain the
excessive A𝛽
42
production in these patients. Recent findings
suggest that pathological changes that occur in AD brain,
such as synapses and neuronal loss, even excess beta amyloid
production, could be causally induced by mitochondrial
dysfunction and increased oxidative stress [4–7]. Different
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studies have demonstrated that mitochondrial levels and
complex IV activity are affected by amyloid-𝛽 [5, 8, 9],
while other findings show that mitochondrial dysfunction
via reactive oxygen species (ROS) production enhanced A𝛽
levels in the central nervous system (CNS) [10].
On the other hand, peripheral tissues of AD patients,
such as platelets—where no elevated A𝛽 levels were found—
showed mitochondrial dysfunction with enhanced ROS for-
mation and increased oxidative stress. In particular, many
evidences from several studies have demonstrated a decrease
in cytochrome C oxidase activity (also known as complex
IV) in platelets from AD patients [11–13]. In accordance with
these findings, platelets from AD patients showed decreased
ATP levels and increased ROS levels [12]. In addition mito-
chondrial membrane potential (MMP) was found to be
reduced in ageing and in AD platelets in comparison with
younger cells [14].However, platelets are not suitable to evalu-
ate the influence of nuclear-encoded proteins in maintaining
mitochondria functionality in response to either physiologi-
cal needs or pathological conditions. To our knowledge only
a few contradictory studies have evaluated the mitochondrial
functionality in lymphocytes derived from sporadic AD
patients: two previous reports found no changes in the
respiratory chain complexes activity in AD lymphocytes [15,
16], while more recently Feldhaus et al. [17] demonstrated
an altered activity of respiratory complexes II and IV in AD
lymphocytes compared with healthy subject blood cells.
Crucial for the maintenance of proper mitochondrial
health and function is an intricate bigenomic program,
involving both nuclear and mitochondrial genomes [18, 19].
For example, replication and transcription of mitochondrial
genome are regulated by the action of a combination of pro-
teins encoded by the nucleus, including (a) the peroxisome
proliferator activator receptor gamma-coactivator 1𝛼 (PGC-
1𝛼) [20], (b) themaster regulator ofmitochondrial biogenesis,
(c) the mitochondrial transcription factor A (TFAM), (d)
RNA polymerase (POLRMT), (e) the transcription factors 1
and 2 (TFB1, TFB2), and (f) the nuclear respiratory factors
1 and 2 (NRF1, NRF2). Furthermore, the functionality of
mitochondrial respiratory chain depends on both nuclear
and mitochondria encoded proteins, as part of the electron
transport chain (ETC), and of the Krebs cycle, involved in
ATP synthesis [21].
Therefore, to further investigate mitochondrial alter-
ations in AD pathology, we focused on studying particular
mitochondrial-encoded and nuclear-encoded protein levels
in peripheral blood mononuclear cells (PBMCs) isolated
from AD and Mild Cognitive Impairment (MCI) patients.
2. Materials and Methods
2.1. Subjects. Patients affected by Alzheimer’s disease (20)
and Mild Cognitive Impairment (24) and (30) healthy age-
matched controls were enrolled at the Neurology Unit
of Cabuen˜es Hospital, Asturias (Spain). Subjects received
a diagnosis of probable or possible AD according to
NINCDS/ADRDA criteria (National Institute of Neurolog-
ical and Communicative Disorders and Stroke/Alzheimer’s
Table 1: Demographic and clinical characteristics of subjects/
patients used in the study.
(a) Spanish cohort
CTL MCI AD
𝑛 (M; F) 30 (16; 14) 24 (14; 10) 20 (8; 12)
Mean age ± SD (years) 71 ± 8 73 ± 6 74 ± 7
MMSE 29 ± 1 27 ± 2 24 ± 3
CDR 0 0.5 1
Disease onset 71.7 ± 6.49 71.67 ± 8.27
LOI (months) 24.5 ± 14.36 26.8 ± 13.25
(b) Italian cohort
CTL MCI AD
𝑛 (M; F) 248 (116; 131) 70 (44; 26) 276 (99; 177)
Mean age ± SD (years) 75 ± 9.98 71 ± 8.71 78.23 ± 7.37
MMSE 29 ± 1 25.3 ± 4.45 15.1 ± 6.23
CDR 0 0.52 ± 0.06 2 ± 1
Disease onset 69.6 ± 6.2 72.5 ± 7.5
LOI (months) 30.2 ± 12.3 43 ± 31
AD: Alzheimer’s disease; CTL: control; F: female; M: male; MMSE: Mini-
Mental State Examination; CDR: Clinical Dementia Rating; LOI: length of
illness; and 𝑛: number. Data are expressed as mean ± SD.
Disease and Related Disorders Association), whereas MCI
diagnosis followed the criteria of Petersen et al. when there
was evidence ofmemory impairment, preservation of general
cognitive and functional abilities, and absence of diagnosed
dementia. Furthermore, depending on the patient’s clinical
profile, other tests of personalized assessment were per-
formed. Recruited healthy controlsmet the following criteria:
(1) no history of past or current psychiatric or neurologic
disorders and (2) a score of higher than 26 in the Mini-
Mental State Examination (MMSE). All patients included in
this study underwent neuroimaging and neuropsychological
assessment following the American Academy of Neurology
(AAN) recommendations. Subjects with other neurological
and psychiatric diseases as well as patients with a history of
alcohol or drug abuse were excluded from the study. Besides
this, subjects with acute comorbidities were also excluded.
In addition, none of the subjects were taking antioxidant
supplements.The ethical committee approved the protocol of
the study, including the follow-up visits, and written consent
was obtained from all subjects or, where appropriate, their
caregivers. The demographic and clinical characteristics of
the donors are shown in Table 1(a). PBMCs were obtained by
Ficoll fractions of fresh blood [22] and were further used to
obtain total protein extracts and DNA samples.
In addition DNA samples derived from 276 patients
with sporadic AD, 70 patients with MCI, and 248 healthy
age-matched controls (Table 1(b)) were obtained from the
Institute “Fondazione Casimiro Mondino” and “Santa
Margherita” in Pavia and from Sant’Orsola Hospital in
Brescia, Northern Italy. The details of the enrollments were
reported in Lanni et al. [23, 24].
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2.2. Mitochondrial Enzyme Activity. Citrate synthase activity
was measured spectrophotometrically at 412 nm at 25∘C in
whole cell extracts using a citrate synthase assay kit (Sigma-
Aldrich, St. Louis, MO). Cell homogenates were added to
buffer containing 10mM 5,5-dithiobis-2-nitrobenzoic acid,
10mM oxaloacetate, lM EDTA, 30mM acetyl CoA, 5mM
triethanolamine hydrochloride, and 0.1M Tris-HCl pH 8.1.
Citrate synthase activity was expressed as 𝜇mol of citrate
produced/min/mL. Cytochrome C oxidase activity was mea-
sured spectrophotometrically at 550 nm at 25∘C in whole
cell extracts using a cytochrome C oxidase assay kit (Sigma-
Aldrich, St. Louis, MO). Cell homogenates were added to
buffer containing 10mM Tris-HCl pH 7.0, 250mM sucrose,
0.22mM ferrocytochrome c, and 0.5mM DTT. Cytochrome
C oxidase activity was expressed as units of oxidized ferrocy-
tochrome c/min/mL per minute at pH 7.0 at 25∘C.
2.3. Western Blot and Immunoprecipitation. Protein samples
(30 𝜇g each) were electrophoresed in 10% Acrylamide Gel
and electroblotted onto nitrocellulose membranes (Sigma-
Aldrich, St. Louis, MO). Membranes were blocked for 1 h in
5% bovine serum albumin in TBS-T (0.1m Tris-HCl, pH 7.4,
0.15m NaCl, and 0.1% Tween 20) and incubated overnight
at 4∘C with primary antibodies (described below). Protein
extracts were processed for Western blot analysis. Primary
antibodies were anti-MnSOD (1 : 200, Sigma Aldrich) and
anti-tubulin (1 : 1000, Sigma-Aldrich). IRDye near-infrared
dyes-conjugated secondary antibodies (LI-COR, Lincoln,
Nebraska, USA) were used. The immunodetection was per-
formed using a dual-modeWestern imaging system Odyssey
FC (LI-COR Lincoln, Nebraska, USA). Quantification was
performed using Image Studio Software (LI-COR, Lincoln,
Nebraska, USA) and the results were expressed as a ratio
between MnSOD and tubulin fluorescent signal.
To analyze nitrated MnSOD, we immunoprecipitated
3NT-proteins with 𝜇MACS Protein A/GMicroBeads (MACS
Technology, Miltenyi). Specifically, 50 𝜇g PBMC protein
extracts were incubated on ice for 30 minutes with 50 𝜇L
of the 𝜇MACS Protein A/G MicroBeads coated with 2 𝜇g
of anti-3NT antibody (Sigma-Aldrich, St. Louis, MO, USA).
After the incubation period, the magnetizable immune
complex was passed over a separation column and placed
in the magnetic field of a MACS Separator. At this stage
magnetically labeled proteins were retained in the 𝜇 columns,
while other proteins were efficiently washed away with 5
washes using RIPA buffer. Subsequently elution buffer was
added and nitrated proteins were collected in a fresh tube.
Cell lysate, washes, and elution were loaded onto 10% SDS-
PAGE gels, followed by immunoblotting the nitrocellulose
membranes with anti-MnSOD antibody as shown above.
2.4. ELISA Immunoassay. For ELISA 70 𝜇g of nondenatu-
rated protein extracts was diluted in PBS 1x pH 7.4 and coated
on the ELISA microplate overnight at 4∘C. The next day
plates were saturated with 100 𝜇L/well of blocking solution
(PBS pH 7.4, 0.1% Tween 20, and 3% bovine serum albumin
(BSA)) and incubated for 1 h at room temperature, followed
by 2 h incubation at 37∘Cwith anti-PGC-1𝛼 (0.5 𝜇g/mL), anti-
TFAM (0.5 𝜇g/mL), anti-cytochrome B (0.5 𝜇g/mL), or anti-
cytochrome C (0.5 𝜇g/mL) antibodies. After washing with
PBST (PBS pH 7.4 and 0.5% Tween 20), 0.1mg/mL anti-
mouse secondary antibody conjugated with peroxidase was
incubated in each well for 1 h at room temperature. Finally,
100 𝜇L of TMB (3,3,5,5-tetramethylbenzidine) substrate was
added and the reaction was stopped with 100 𝜇L 2M sulfuric
acid. Optical density was measured using a microplate reader
at a wavelength of 450 nm. Data were extrapolated by a stan-
dard curve created with serial dilution of the corresponding
recombinant protein and then were expressed as the median
± SEM.The experiments were performed in triplicate.
2.5. Mitochondrial DNA Analysis. Total DNA was extracted
from PBMCs with QIAamp DNA extraction kit (Qiagen,
Hilden, Germany), and mtDNA was amplified using primers
specific for the mitochondrial cytochrome B (CYT B) gene.
Mitochondrial DNA copy number was normalized to nuclear
DNA copy number by amplification of the acidic ribosomal
phosphoprotein P0 (Arbp/36B4) nuclear gene. Primer
sequences were designed using Beacon Designer 2.6 software
(Premier Biosoft International, Palo Alto, CA, USA). The
primers used were the following: for CYTB forwards 5󸀠-
GCCTGCCTGATCCTCCAAAT-3󸀠 and reverse 5󸀠-AAG-
GTAGCGGATGATTCAGCC-3󸀠, 36B4 forwards 5󸀠-AGG-
ATATGGGATTCGGTCTCTTC-3󸀠 and reverse 5󸀠-TCA-
TCCTGCTTAAGTGAACAAACT-3󸀠.
2.6. Statistical Analysis. Results were given as median ±
SEM or mean ± SEM values, according to the experiment.
Statistical significance of differences was determined bymean
values of both 𝑡-test and one-way ANOVA, followed by the
Bonferroni test. Significance was accepted for 𝑝 < 0.05.
Statistical analyses were performed using Graph Pad Prism
(Graph Pad Software Inc., San Diego, CA, USA) version 4.0.
3. Results
3.1. Biochemical Properties ofMitochondria in PBMCsDerived
from AD and MCI Patients. PBMCs derived from 20 AD, 24
MCI patients and 30 age-matched controls were evaluated by
measuring the protein levels of two redox cofactors, involved
in the transfer of electrons through ETC complexes, and
the activity of two enzymes, which gave the efficiency of
mitochondrial functionality. In addition the amount of mito-
chondrial DNA (mtDNA) was also assessed. In particular,
protein levels of cytochrome B (CYT B), a component of
respiratory chain complex III [25], and cytochrome C (CYT
C), a small heme-protein involved in the transfer of electrons
between complexes III and IV [26], were evaluated in the
three different groups by ELISA. As depicted in Figure 1(a),
CYTBprotein level was statistically reduced inAD, but not in
MCI PBMCs (median ± SEM; CTL 1.19±0.061 ng versus AD
0.84 ± 0.006 ng; 𝑝 < 0.001). While CYT C was decreased in a
significantmanner in bothAD andMCI, it is anyway lower in
MCI when compared with healthy subjects (median ± SEM;
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Figure 1: Mitochondrial protein levels in PBMCs derived from AD, MCI patients and healthy controls. Cytochrome B (CYT B) (a) and
cytochrome C (CYT C) (b) levels were measured by ELISA in protein extracts derived from PBMCs.The values are expressed as ng of protein
and are referred to as specific standard curves. Data was expressed as median ± SEM. The statistical significance was represented by the
asterisks as follows: ∗∗𝑝 < 0.001; ∗∗∗𝑝 < 0.0001 versus corresponding control group.
CTL 0.89 ± 0.037 ng versus AD 0.58 ± 0.063 ng; 𝑝 < 0.001;
MCI 0.46 ± 0.060 ng; 𝑝 < 0.0001).
Furthermore the mitochondrial functionality was esti-
mated bymeasuring the activity of two enzymes, cytochrome
C oxidase (complex IV) and citrate synthase, involved in
oxidative metabolism and Krebs cycle, respectively. These
two enzymes were found to be significantly higher in MCI
subjects compared to the control group (median ± SEM;
cytochrome C oxidase: CTL 0.035 ± 0.0015 units oxidized/
mL/min versus MCI 0.10 ± 0.0013 units oxidized/mL/min;
𝑝 < 0.0001; citrate synthase: CTL 0.131 ± 0.0011 𝜇mole
produced/mL/min versus MCI 0.25 ± 0.033 𝜇mole pro-
duced/mL/min𝑝 < 0.0001) (Figures 2(a) and 2(b)).However,
if cytochrome C oxidase activity was expressed as the ratio
to citrate synthase, no differences were found between MCI
and control groups (Figure 2(c)). At variance, AD group
showed only a slight, but statistically significant increase of
cytochrome C oxidase activity (median ± SEM; CTL 0.035 ±
0.0015 units oxidized/mL/min versus AD 0.15 ± 0.014 units
oxidized/mL/min; 𝑝 < 0.05), whereas no differences were
observed inAD citrate synthase activity compared to controls
(Figures 2(a) and 2(b)). As a result, also the cytochrome C
oxidase/citrate synthase ratio was increased in these patients
when compared with controls (median ± SEM; CTL 0.28 ±
0.02 versus AD 0.36 ± 0.06; 𝑝 < 0.05) (Figure 2(c)).
Since electron transport chain efficiency was directly
correlated with the ROS generation as a byproduct of respira-
tory metabolism [27], and with the efficiency of antioxidant
response, MnSOD enzyme was also evaluated. In particular
MnSOD expression was studied by Western blot analysis
(WB) using an anti-MnSODmonoclonal antibody on 6 CTL,
6 AD, and 6 MCI samples. In addition an immunoprecip-
itation experiment (ip) with an antibody that recognized
the nitrated tyrosine residues (anti-3NT), followed by a WB
with anti-MnSOD, was performed on the same samples.
Figures 3(a)-3(b) show a representative WB and ip of 2
CTL, 2 AD, and 2 MCI samples. The amount of MnSOD
(MnSODtot) did not significantly differ among controls and
AD andMCI patients, although its levels tended to be higher
in controls than in AD and MCI patients (Figures 3(a)–
3(c)). The expression of MnSOD
3NT, evaluated as the ratio
between the nitrated and 3NT-free isoform, was found to
be higher in the MCI and AD in comparison with control
samples (Figure 3(b)). The analysis of fluorescence signals of
all samples examined (6 CTL, 6 AD, and 6 MCI) showed a
significant enhancement of MnSOD
3NT in both AD andMCI
patients when compared with controls (Figure 3(d)).
Another parameter evaluated to study mitochondria
status was the mitochondrial DNA content, measured as the
amount of mitochondrial DNA copy number normalized to
nuclear DNA copy number [19]. In particular, the ampli-
fication of cytochrome B (mitochondrial gene) and 36B4
(nuclear gene) was obtained by real time PCR. The amount
of mtDNA was found to be lower in AD and MCI patients
in comparison with the control group (mean ± SEM; CTL
13.93 ± 2.26 versus AD 3.43 ± 0.69; 𝑝 < 0.0001; CTL 13.93 ±
2.26 versus MCI 6.99 ± 0.71; 𝑝 < 0.001) (Figure 4(a)).
mtDNA content was also measured in DNA samples
derived from a larger cohort, composed of 248 healthy aged-
matched controls and 70 MCI and 276 AD patients [23, 24].
As depicted in Figure 3(b), mtDNA content was significantly
lower in AD and MCI patients than in the control group,
confirming the results above (mean ± SEM; CTL 12.00± 3.73
versus AD 6.82 ± 2.85; 𝑝 < 0.0001; CTL 12.00 ± 3.73 versus
MCI 5.05 ± 2.39; 𝑝 < 0.0001) (Figure 4(b)).
Finally, we attempted a correlation between mtDNA con-
tent and MMSE, considering both recruitments altogether.
Loss of mtDNA content positively correlated with cognitive
decline, measured as MMSE score (𝑟2 = 0.034, 𝑝 = 0.0002)
(Figure 4(c)).
3.2. Expression of PGC-1𝛼 and TFAM in PBMCs Derived
from AD and MCI Patients. It is well established that
the maintenance of mitochondria machine is under the
control of nuclear transcription factors in a hierarchical
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Figure 2:Mitochondrial protein activity in PBMCsderived fromAD,MCIpatients andhealthy controls. CytochromeCoxidase (a) and citrate
synthase (b) activity was measured spectrophotometrically (see Section 2). The data were expressed as 𝜇mole of enzyme produced/mL/min
for citrate synthase activity and as units of enzyme oxidized/mL/min for cytochromeC oxidase. (c) Ratio between cytochromeC oxidase (cox)
and citrate synthase (cs) was expressed as median ± SEM. The statistical significance was represented by the asterisks as follows: ∗𝑝 < 0.05;
∗∗∗𝑝 < 0.0001 versus corresponding control group.
structure [28, 29]. In order to investigate a possible role of
nuclear-encoded proteins in mitochondrial impairment in
AD and MCI blood cells, we evaluated the protein levels of
PGC-1𝛼 and TFAM, by ELISA assay, in the three groups.
Specifically, PGC-1𝛼 is a positive regulator of mitochondrial
biogenesis and respiration that increases mitochondrial
function and minimizes the build-up of byproducts, while
TFAM is a target gene of PGC-1𝛼 that regulates replication
and transcription of the mitochondrial genome and its
expression is directly correlated with the mtDNA content
[28, 29]. As shown in Figures 5(a) and 5(b) a statistically
significant reduction of PGC-1𝛼 and TFAM was found
in AD patients if compared with age-matched controls
(median ± SEM PGC-1𝛼: CTL 0.11 ± 0.02 ng versus AD
0.08 ± 0.04 ng; 𝑝 < 0.05; TFAM: CTL 5.16 ± 0.74 ng versus
AD 4.12 ± 0.94 ng; 𝑝 < 0.0001). Interestingly MCI PBMCs
showed a significant decrease of TFAM protein expression
(median ± SEM, CTL 5.16 ± 0.74 ng versus MCI 3 ± 0.81 ng;
𝑝 < 0.001), while PCG-1𝛼 was unchanged when compared
with control samples (Figures 5(a) and 5(b)).
3.3. Cognitive Decline versusMitochondrialMarkers. In order
to give more insight into the relationship between the
progression of the disease and mitochondrial impairment,
correlation studies between cognitive status and the markers
reported above were performed. No association between
CYT B and cognitive decline was found (data not shown).
At variance, CYT C, PGC-1𝛼, or TFAM expression positively
correlated with MMSE score in a statistically significant
manner (CYTC: 𝑟2 = 0.189; 𝑝 = 0.0006; PGC-1𝛼: 𝑟2 = 0.171;
𝑝 = 0.0008; TFAM: 𝑟2 = 0.175; 𝑝 = 0.0009) (Figures
6(a)–6(c)). In addition, TFAM also correlated with mtDNA
content (𝑟2 = 0.117; 𝑝 = 0.01), confirming its role in
regulating mtDNA transcription (Figure 6(d)).
4. Discussion
The arrangement of the mitochondria machine requires the
well-coordinated action of both mitochondrial and nuclear
proteins. In fact, the modulation of the electron transport
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Figure 3: MnSOD level and its nitrated isoform in PBMCs derived from AD, MCI patients and healthy controls. Protein extracts derived
from PBMCs of AD, MCI, and control were processed for Western blot analysis and immunoprecipitation assay (ip). (a) A representative
immunoblot of protein extracts derived from 2 controls, 2 AD, and 2 MCI carried out with anti-MnSOD antibody. Tubulin was used to
normalize the samples. (b)The 3NT-enriched fractions and 3NT-free washed fractions derived from ip experiments of the same 2 controls, 2
AD, and 2 MCI were loaded onto 12% SDS-PAGE gels and immunoblotted with anti-MnSOD antibody. (c) Quantitative analysis of MnSOD
levels of 6 AD, 6 MCI, and 6 control samples expressed as MnSOD expression over 𝛼-tubulin levels. (d) Quantitative analysis of MnSOD
nitrated isoformover 3NT-free isoformperformed on 6AD, 6MCI, and 6 control samples. Data were expressed asmean± SEM.The statistical
significance was represented by the asterisk ∗𝑝 < 0.05 versus the corresponding control group.
respiratory chain, and accordingly of energy production, is
the result of a crosstalk betweenmitochondria and the signals
derived from the cellular environment. So, for example, cellu-
lar pathways involved in inflammatory and calcium signaling
modulate mitochondrial activities and mitochondrial mass
[30–38]. Furthermore ROS have been proposed as one of the
signaling molecules that induce mitochondria activities via
PCG-1𝛼 protein enhancement [39, 40].
Herewe investigatedwhether nuclear andmitochondrial-
encoded proteins, involved in both mitochondrial activity
and the maintenance of mitochondrial DNA, were involved
in mitochondrial dysfunction in AD pathology.
In particular we demonstrated that both CYT B and
CYT C were compromised in PBMCs of AD patients,
while only CYT C was found decreased in MCI blood
cells if compared with age-matched controls, suggesting a
progressive mitochondria impairment in the development
of the disease. CYT B and CYT C, of mitochondrial and
nuclear origin, respectively, are key cofactors ofmitochondria
machine participating in the transfer of electrons through
complexes III and III-IV. Interestingly decreased CYT C
expression positively correlated with the cognitive decline,
measured as MMSE score.
Surprisingly, MCI PBMCs showed higher activities of
two enzymes regulating the energy machine, cytochrome C
oxidase and citrate synthase, involved in the respiratory chain
processes andKrebs cycle, respectively. On the other hand the
ratio of cytochrome C oxidase to citrate synthase, that better
correlate the data with the mitochondria number, did not
differ between MCI and control groups. Differently AD cells
showed a slight increase of cytochrome C oxidase activity,
confirmed also by the ratio of cytochrome C oxidase/citrate
synthase. An increase of cytochrome C oxidase activity in
different brain areas of ADmice overexpressing beta amyloid
was also demonstrated by Strazielle et al. [41]. On the other
hand, it must be stressed that contradictory results were
reported regarding the activity of respiratory chain complexes
in peripheral cells. For example, Feldhaus et al. [17] showed an
increased energy metabolism in lymphocytes derived from
AD, while Valla et al. [11] found a reduction in the activity
of complexes III and IV in mitochondria isolated from blood
platelets of AD patients. In our opinion, such discrepancies
might be due to the different cellular phenotypes examined
as well as to the different grades of illness severity.
Furthermore a significant statistical increase of the
MnSOD nitrated isoform was observed in the AD and MCI
Oxidative Medicine and Cellular Longevity 7
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Figure 4:mtDNA copy content in PBMCs derived fromAD,MCI patients and healthy controls. mtDNA content wasmeasured as the amount
of cytochrome B copy number (mitochondrial DNA) normalized to 36B4 gene copy number (nuclear DNA) by real time PCR in Spanish
(a) and Italian (b) DNA samples. Data was expressed as mean ± SEM.The statistical significance was represented by the asterisks as follows:
∗∗𝑝 < 0.001; ∗∗∗𝑝 < 0.0001 versus the corresponding control group. The values of mtDNA content of both Spanish and Italian cohort were
also correlated with the corresponding values of MMSE score (c). mtDNA content/MMSE (𝑝 = 0.0002 and 𝑟2 = 0.03).
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Figure 5: PGC-1𝛼 and TFAM protein levels in PBMCs derived from AD, MCI patients and healthy controls. PGC-1𝛼 (a) and TFAM (b)
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Figure 6: Correlation between CYT C, PGC-1𝛼, or TFAM proteins with cognitive decline. The values of CYT C (a), PGC-1𝛼 (b), or TFAM
(c) in protein extracts derived from PBMCs were correlated with the corresponding values of MMSE score. ng of CYT C/MMSE, 𝑟2 = 0.189,
𝑝 = 0.0006; ng of PGC-1𝛼/MMSE, 𝑟2 = 0.171, 𝑝 = 0.0008; ng of TFAM/MMSE, 𝑟2 = 0.175, 𝑝 = 0.0009. (d) The values of TFAM were also
correlated with the corresponding values of mtDNA content (𝑟2 = 0.117, 𝑝 = 0.01).
groups, although the levels of the antioxidant enzyme in
the two groups did not substantially differ from controls. A
long lasting exposure to a prooxidant environment could be
responsible for the MnSOD nitrated isoform enhancement.
In line with our data, different authors reported that neurons
derived from APP/PS1 tg mice showed decreased MnSOD
activity, due to the nitration of its tyrosine residues [42, 43].
Mitochondria are the major sources of intracellular ROS, but
they are also particularly vulnerable to oxidative stress [42].
We recently demonstrated, in immortalized lymphocytes
derived from both familiar and sporadic AD, an increased
nitrosative stress that affected protein function. In particular,
nitration at tyrosine residues of the p53 protein compromised
its wild type tertiary structure as well as its function [44].
Thus, although ROS act as signaling molecules to activate
MnSOD via SIRT3, a PGC1-𝛼-target, as a compensatory
mechanism [39], it is also true that a sustained exposure to a
prooxidant environment leads to a loss of adaptive response.
We also measured the amount of mtDNA in DNA
samples from two different cohorts. The mtDNA content
was found to be statistically decreased in MCI and AD of
both groups if compared with control samples. However, it
has to be stressed that the mean values of the Spanish MCI
mtDNA content were found to be higher than that found
in the Italian MCI DNA samples. This may be due to the
different degree of cognitive decline in the two MCI groups;
in fact the mean MMSE score was two points higher in the
Spanish MCI compared with Italian patients. The number
of mitochondria is cell specific and varies depending on
the energetic requirement of the cells. It is also influenced
by many factors, including the environmental and redox
balance of the cell, the differentiation stage, and the number
of cell signaling mechanisms [44–46]. Malik and Czajka
[47] proposed the theory that the mtDNA content could be
a biomarker of mitochondrial dysfunction. The premise of
this theory is that values of mtDNA copy number, related
to the value of nuclear DNA content, of a particular cell,
normally within a healthy range, could change in condition
of oxidative stress: the initial response to increased oxidative
stress would be an adaptive response where the ratio between
mtDNA and nuclear DNA would increase as a result of
increasedmitochondria biogenesis; persistent oxidative stress
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may lead to the depletion ofmtDNAalongsidemitochondrial
dysfunction, resulting from damaged mtDNA and proteins.
According to this theory, loss of mtDNA positively correlated
with the cognitive decline, measured as MMSE score.
It is well established that the maintenance of mtDNA is
under the control of nuclear transcription factors. The core
machine ofmitochondrial gene expression consists of TFAM,
RNApolymerase 𝛾 (POLRMT), andmitochondrial transcript
factor B2 (TFB2). TFAM has an additional role in packaging
of mtDNA and it is necessary for mtDNA maintenance [48,
49]. TFAM is under the control of PGC-1𝛼, which is upstream
of all the pathways that regulate the expression of nuclear-
encodedmitochondrial factors, and for this reason it is called
the “master regulator” of mitochondrial biogenesis. In this
study PGC-1𝛼 was found to be reduced only in AD but
not in MCI PBMCs. In accordance with our findings, an
involvement of PGC-1𝛼 in AD pathology was demonstrated
in transgenic ADmodels and the ectopic expression of PGC-
1𝛼 in a cell model of AD ameliorated their phenotype [50–
52]. Nevertheless more importantly we found that TFAM
expression was already significantly lower in MCI blood
cells when compared with control PBMCs, suggesting its
involvement in early stage of AD pathology. It is noteworthy
that independent studies have demonstrated TFAM-gene
variation as a moderate risk factor for AD development [53].
TFAM polymorphism Ser12Thr, that affects its function, was
more highly common in the AD patients compared with
healthy control groups [54].
Furthermore both PGC-1𝛼 and TFAM well correlated
with cognitive decline. In addition TFAM positively corre-
lated alsowithmtDNA content, confirming its important role
in the regulation of mitochondrial genome.
Consistent evidence demonstrates that mitochondrial
failure affecting replication and transcription of mtDNA is a
feature ofmany ageing-related disorders: from cardiovascular
to neurodegenerative diseases, suggesting that probably a
common mechanism could be involved [55, 56]. The fact
that such alterations were appreciated in the early stages of
AD might help in the differential diagnosis supporting the
current neuropsychological tests. However, further studies
on a large number of patients have to be performed to
better understand if TFAM reduction and decreased mtDNA
content could be potentially a blood-based signature of AD.
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